Multicenter Randomized Trial Evaluating the Efficacy of Cilostazol on Ischemic Vascular Complications After Drug-Eluting Stent Implantation for Coronary Heart Disease

摘要: Objectives We aimed to test whether cilostazol has beneficial effects in the real-world patients treated with intracoronary drug-eluting stents (DES). Background The addition of on conventional dual antiplatelet therapy been reported reduce platelet reactivity and improve clinical outcomes after percutaneous coronary intervention previous studies. Methods In a randomized multicenter trial, we enrolled 960 who received DES. They were receive either (DAT) (aspirin clopidogrel) or triple (TAT) (aspirin, clopidogrel, cilostazol) for 6 months. Primary end point was composite cardiac death, nonfatal myocardial infarction, ischemic stroke, target lesion revascularization (TLR). Secondary points P2Y 12 reaction unit (PRU) measured VerifyNow P2Y12 assay (Accumetrics, San Diego, California) at discharge months index procedure. All-cause stent thrombosis, each component primary other secondary points. Analysis done an intention-to-treat basis. Results At months' follow-up, there no difference between 2 groups (8.5% TAT vs. 9.2% DAT, p = 0.74). analysis, group achieved lower PRU levels than DAT both (206.6 ± 90.3 232.2 80.3 PRU, Conclusions Despite greater reduction by did not show superiority reducing adverse cardiovascular DES implantation. (The Efficacy CILostazol ON Ischemic Complications After Implantation [CILON-T]; NCT00776828 )